EC Number   |
Application |
Reference |
|---|
    1.11.1.8 | analysis |
development of an ELISA system for quantitative determination of TPO in biological fluids, based on the use of an analytical pair of monoclonal antibodies, one of which is immobilized on solid phase, the other being present in solution. The use of this system made it possible to determine the biochemical characteristics of immunoaffinity chromatography of the enzyme and propose a new method for obtaining a highly purified preparation of its protein |
671397 |
| 1.11.1.8 | analysis |
evaluation of a rapid assay for TPO inhibition, using a stable fluorescent product (Amplex UltraRed). The assay consistently identifies the relative potency of strong to moderate inhibitors and chemicals known to be inactive. Results are less consistent for chemicals reported to be weak inhibitors of rodent TPO |
765855 |
| 1.11.1.8 | medicine |
addition of TPO stain and proliferation marker Ki-67 stain to routine Papanicolaou stain may improve the diagnostic reliability of fine-needle aspiration cytology for follicular carcinoma with high degree of malignancy |
742347 |
| 1.11.1.8 | medicine |
amino acids from TPO region 713-717 are the key residues, recognized by IDR/B-specific anti-TPO autoantibodies in autoimmune thyroid disease. These data are of great importance to rationally design therapeutic peptides able to block undesired autoimmune responses |
659385 |
| 1.11.1.8 | medicine |
analysis of of TPO immunohistochemical expression in thyroid nodules with signs or symptoms suspicious for malignancy. TPO may be useful in confirming or ruling out benign diseases from differentiated thyroid carcinoma, with the exception of low-risk carcinoma such as minimally invasive follicular carcinoma |
743866 |
| 1.11.1.8 | medicine |
identification of TPO gene defects in a cohort of patients with thyroid dyshormonogenesis from Slovenia, Bosnia, and Slovakia. The high percentage of single allele mutations implies possible intronic or regulatory TPO gene mutations or monoallelic expression |
686508 |
| 1.11.1.8 | medicine |
R646 and D707 together with R225 constitute a functional epitope within IDR-A, and that residues E604, D620, and D630, together with K627, constitute a functional epitope within IDR-B. The identification of key residues within the autoreactive epitopes will help in understanding the structural basis for the breakdown of immune tolerance to TPO in thyroid autoimmune disease |
673355 |
| 1.11.1.8 | medicine |
TPO transcripts are present in both normal and cancer tissue samples patients with breast cancer. TPO levels are lower in more advanced cancers. The antigenicity of the immunodominant regions in breast TPO resembles that of thyroid TPO |
743621 |
| 1.11.1.8 | medicine |
two patients with iodide organification defect caused by two compound heterozygous mutations, c.215delA/c.2422T-->C [p.Q72fsX86/p.C808R] and c.387delC/c.1159G-->A [p.N129fsX208/p.G387R], in the TPO gene and four patients with monoallelic TPO defect. Identification of the molecular basis of this disorder might be helpful for understanding the pathophysiology of congenital hypothyroidism |
686168 |
| 1.11.1.8 | synthesis |
baculovirus-mediated expression of a truncated recombinant TPO proteine. The signal peptide from the peptidyl-glycine alpha-amidating monooxygenase significantly promotes the secretion in High Five cells when fused to TPO. An optimized scale-up production procedure for TPOt in a 5-L wave-type bioreactor and subsequent purification achieving a protein purity of >95% give a protein with high sensitivity and specificity in reactions with positive or negative human serum samples via the double-antigen sandwich method |
765708 |
